Verge joins Genomics England’s Discovery Forum industry partnership

Verge Genomics joins the Discovery Forum to transform pioneering research into frontline patient treatments.

Genomics England and Verge Genomics, a leading artificial intelligence therapeutics company, announced today that Verge will join Genomics England’s Discovery Forum industry partnership. The partnership aims to translate groundbreaking research into innovative treatments, and ultimately patient benefit, as rapidly as possible.

The Discovery Forum provides an engagement platform for industry partners, academia, the NHS, and the wider genomics community. More than 30 of the world’s leading genomics companies come together within the Forum to work in a pre-competitive environment with access to whole genome sequences from the 100,000 Genomes Project.

Verge brings additional strengths to the Discovery Forum, with its extensive and growing network of data partnerships. In late 2017, Verge announced two public-private partnerships with a dozen academic and national institutions, leading to the creation one of the world’s largest collections of ALS and Parkinson’s Disease patient data. In January 2018, Verge announced a collaboration with Datavant, a Roivant Sciences-backed company focused on data aggregation to improve clinical trials, to unlock the value of one of the world’s most extensive collections of patient genomes and clinical data.

Alice Zhang, Verge Genomics CEO, said:

Verge is committed to integrating datasets held by industry, academic and government partners, because we believe that shared understanding will drive ever more effective treatments for patients around the world. We are honored to share this mission with Genomics England.

Professor Joanne Hackett, Genomics England Chief Commercial Officer, said:

Industrial partnership is critical to unlocking the true potential of genomic medicine. In combining the unique scale and richness of the Genomics England dataset with the expertise and relentless innovation of companies such as Verge, we can rapidly turn pioneering research into frontline patient care.